Speaker
Ryszard Lauterbach
- Jagiellonian University
- Poland
Presentation
Why should we reduce inflammatory responses in neonatal sepsis?
- April 08-09, 2027
- Dubai, UAE
Biography
Professor Ryszard Lauterbach is a distinguished Polish physician and academic specializing in pediatrics and neonatology. He is affiliated with the Jagiellonian University Medical College in Kraków, Poland, where he has made significant contributions to neonatal clinical care, medical education, and research. He graduated from the Medical Academy in Kraków and obtained his medical doctorate in 1985, followed by his habilitation in 1996. He received the title of Professor in 2002. His professional career has focused extensively on improving neonatal intensive care and advancing treatment approaches for critically ill and premature newborns. His principal research interests include neonatal sepsis, non-invasive respiratory support for newborns, and the optimization of parenteral nutrition. His work has contributed to developments in neonatal infection management, respiratory support, and nutritional strategies for premature infants. Professor Lauterbach has held several important academic and professional leadership positions. He served as a regional consultant in neonatology from 1994 and was President of the Polish Neonatal Society from 2019 to 2023. He has also contributed to scientific research administration and medical education at Jagiellonian University. With an extensive body of scientific publications, book chapters, and academic contributions, Professor Lauterbach continues to be recognized for his work in advancing neonatal medicine and improving healthcare outcomes for newborns.
Abstract
Sepsis is still one of the leading causes of neonatal morbidity and mortality. Since 2016 sepsis is defined as a life-threatening organ dysfunction syndrome caused by dysregulated host response to infection. Prematurity is a chronic, hyperinflammatory state compared with adults. Unregulated inflammatory response is partially due to an increase in production of proinflammatory mediators but is also due to the lack of negative regulators. The inflammatory response caused by sepsis in preterm infants impairs the process of myelinization, disrupts the development of white matter tissue, and eventually inhibits brain growth. Apart from TNF-a, IL-6 is the earliest and primary indicator for neonatal sepsis. A retrospective analysis of 480 cases of LOS, diagnosed in 208 preterm infants born before 32 weeks of pregnancy found a significant correlation between the serum IL-6 level and the severity of the clinical course of sepsis and the risk of death. The promising candidate, which exerts several antioxidant and anti-inflammatory activities seems to be pentoxifylline, (PTX), a methylxanthine derivative, a non-specific phosphodiesterase inhibitor. A considerable number of studies demonstrated that PTX reduced serum concentrations of the inflammatory cytokines such as TNF-a and IL-6.
We declare that PTX as an adjunct to antibiotic therapy or suspected sepsis in preterm neonates, has been used in our department continuously since 1999. In 2016, we published the results of sepsis therapy diagnosed in very low birth weight infants. Among the 458 infants with confirmed sepsis (median birthweight 1010.0g; median gestational age: 29 weeks), death occurred in 19 (15 EOS and 4 LOS) of those infants (4.2%).
However, the dosage and schedule of PTX administration have been adjusted to clinical symptoms and the values of IL-6 serum concentrations.
This article reports the case of LOS severe sepsis with extremely increased blood IL-6 concentration with values up to 250.000 pg/ml whereas the cutt-off values for diagnosis, suggested by several authors, range from 40 to 80 pg/mL. Also, it presents the efficacy and safety of a modified, significantly increased dosage of PTX, that have been used to decrease this incredible inflammatory response.